Literature DB >> 12456204

Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes.

James T Mascarello1, Arthur R Brothman, Keri Davison, Gordon W Dewald, Marille Herrman, Danette McCandless, Jonathan P Park, Diane L Persons, Kathleen W Rao, Nancy R Schneider, Gail H Vance, Linda D Cooley.   

Abstract

OBJECTIVE: To assess laboratory performance, use, and limitations in the joint College of American Pathologists and American College of Medical Genetics proficiency testing program for laboratories performing cytogenetic tests based on fluorescence in situ hybridization (FISH). DATA SOURCES: Eight proficiency surveys dealing with FISH detection of microdeletions or microduplications, aneuploidy in interphase cells, gene amplification, and neoplasm-specific translocations. Participating laboratories used their own DNA probes (commercial or home-brew), hybridization methods, and analytic criteria to answer clinical questions about cases represented by slides included in the survey materials. They also described their test results according to the International System for Human Cytogenetic Nomenclature (ISCN) and answered supplementary questions relating to their experience with the subject test systems. DATA EXTRACTION: In addition to evaluating diagnostic accuracy, we evaluated survey use, laboratory experience, variation in methodologic approach, and the practicality of using ISCN nomenclature for describing test results. SYNTHESIS AND
CONCLUSIONS: With the exception of one challenge, at least 80% of the participants reached the correct diagnostic conclusion. In the sole exception, there was still a consensus of 91.7% of participants with the same (albeit erroneous) diagnostic conclusion. The overall outstanding performance of participating laboratories clearly shows the reliability of current FISH methods. Despite the fact that a large number of laboratories reported little or no experience with the specific test systems, the overwhelming majority performed very well. This result shows that the program's strategy of targeting classes of abnormalities (vs a single abnormality associated with a specific disease) did not put at a disadvantage participants who did not routinely perform all of the potential tests in the class. The extraordinary variation in ISCN descriptions submitted by participants showed that the existing system for human cytogenetic nomenclature is not suitable for facile communication of FISH test results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456204     DOI: 10.5858/2002-126-1458-PTFLPF

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

1.  Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Authors:  Michael F Press; Michael A Gordon; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

Review 2.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.

Authors:  Na Zhan; Wei-Guo Dong; Yong-Fei Tang; Ze-Sheng Wang; Cheng-Long Xiong
Journal:  Med Oncol       Date:  2011-02-13       Impact factor: 3.064

4.  Analysis of XPD genetic polymorphisms of esophageal squamous cell carcinoma in a population of Yili Prefecture, in Xinjiang, China.

Authors:  Cong-Gai Huang; Tao Liu; Guo-dong Lv; Qing Liu; Jun-guo Feng; Xiao-mei Lu
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

5.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou C Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

Authors:  Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

7.  Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.

Authors:  Yukie Sato-Kuwabara; José I Neves; José H T G Fregnani; Rubens A Sallum; Fernando A Soares
Journal:  BMC Cancer       Date:  2009-01-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.